Researchers have tested a gene-edited stem cell transplant designed to shield healthy blood-forming cells from powerful cancer-targeting immunotherapies.
For patients with highly aggressive blood cancers, stem cell transplantation can offer a rare chance at a cure — but too often, the cancer returns even after the procedure.
Now, researchers at Washington University School of Medicine in St. Louis have reported encouraging results from a clinical trial designed to make these transplants safer and more effective. The study tested donor stem cells that were genetically engineered to remove a protein called CD33, a target commonly used in follow-up cancer therapies.
The researchers found that eliminating CD33 may help protect healthy cells from the toxic side effects of post-transplant treatments while still allowing those therapies to attack lingering cancer cells. The multi-center trial involved Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine, along with 14 additional sites across the United States and Canada.
The findings, published in Nature Medicine, could open the door to more precise and durable treatments for patients facing some of the most difficult-to-treat blood cancers.
According to senior author John F. DiPersio, MD, PhD, this approach could help solve a major challenge facing CAR-T cell therapy. Although CAR-T treatments have shown success against some blood cancers, they have been far less effective against acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Why CAR-T Therapy Struggles Against AML and MDS
DiPersio explained that AML and MDS are difficult targets because the proteins CAR-T cells are designed to attack on cancer cells are also found on healthy myeloid cells, including donor stem cells used in treatment. As a result, the therapy can destroy healthy blood-forming cells along with cancer cells, increasing the risk of severe inflammation and other toxic side effects. It can also reduce the therapy's effectiveness because many CAR-T cells end up attacking healthy cells instead of the cancer.
The idea behind the new strategy was first developed by Miriam Y. Kim, MD, now an assistant professor of medicine at WashU Medicine. Kim began the work as a postdoctoral researcher at the University of Pennsylvania and later continued the research in DiPersio's laboratory before launching her own research program in oncology at WashU Medicine.

In the trial, patients with AML and MDS received donor stem cells that had CD33 removed before transplantation. Researchers hoped this would allow future CD33-targeted immunotherapies to attack only cancer cells while leaving healthy donor cells unharmed.
CRISPR Removal of CD33 May Protect Healthy Cells
"We are encouraged by the results of this study showing that a CD33-deleted stem cell transplant looks very similar to the outcomes of standard stem cell transplantation," said DiPersio, who also directs WashU Medicine's Center for Gene and Cellular Immunotherapy. "In the future, we are hopeful we will be able to combine this with CD33-targeted immunotherapies, such as CAR-T cells, and improve treatment options for patients with these very aggressive blood cancers."
DiPersio and colleagues also described a separate case involving a patient with high-risk AML who received a CD33-deleted stem cell transplant and later underwent CD33-targeted CAR-T therapy after the cancer returned. The CAR-T treatment used T cells from the same donor who provided the stem cells.
The patient, who had an especially aggressive form of AML, achieved complete remission and remained cancer-free more than a year after CAR-T treatment. Blood cell production also returned to normal, and all blood cells lacked CD33, showing that the edited donor cells had successfully established themselves in the bone marrow. The case study was published in October 2025 in JCO Precision Oncology.
Researchers selected CD33 as a target because it is found mainly on blood-forming cells and not in other tissues. Previous evidence also suggests the protein is not essential for healthy blood stem cell function, since some people naturally lack CD33 without experiencing health problems.
Targeting Cancer Cells While Sparing Donor Stem Cells
After patients receive these edited stem cells, researchers believe that any cells still carrying CD33 should mainly be cancer cells. In theory, this would allow CAR-T cells or other CD33-targeted therapies to destroy the cancer while sparing healthy donor stem cells.
The phase 1/2 trial enrolled 30 adults with AML or MDS who faced a high risk of relapse. Before transplantation, donor stem cells were modified using CRISPR gene editing to remove CD33. The edited stem cell product, known as tremtelectogene empogeditemcel (trem-cel), was developed by Vor Biopharma, which also funded the study.
As part of the study, patients also received gemtuzumab ozogamicin, a maintenance therapy that targets CD33 after transplantation. Although it is not a CAR-T therapy, the treatment uses an engineered antibody linked to an anticancer drug.
Gemtuzumab ozogamicin is already approved by the Food and Drug Administration for CD33-positive AML and is being studied in clinical trials for CD33-positive MDS. Its use has been limited because it can damage the liver and severely reduce blood cell counts, including white blood cells, red blood cells, and platelets.
Clinical Trial Results Demonstrate Feasibility and Safety
All patients in the study achieved stem cell engraftment within 28 days, meaning the transplanted cells successfully settled in the bone marrow and began producing blood cells. Some patients recovered even sooner, with platelet counts returning in an average of 16 days. These recovery times were similar to those seen with standard stem cell transplants.
Average survival exceeded 14 months. Nineteen patients received at least one cycle of maintenance therapy during the dose escalation portion of the study, allowing researchers to determine a recommended dose. Patients maintained stable blood cell counts across all dose levels, suggesting the edited stem cells protected them from the dangerously low blood counts commonly associated with this therapy after standard transplantation.
Side effects were similar to those seen with conventional stem cell transplants and included anemia, low platelet counts, fever, infections, and graft-versus-host disease, a condition in which donor cells attack healthy tissue. Seven patients died during the study. Four deaths were linked to cancer progression, while three were related to transplant complications, including kidney failure, liver toxicity, and sepsis.
DiPersio said the findings provide a foundation for combining CD33-deleted stem cell transplants with CD33-targeted immunotherapies in ways that protect healthy donor cells during cancer treatment.
Reference: "CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial" by John F. DiPersio, Guenther Koehne, Nirali N. Shah, Léa Bernard, Hyung C. Suh, Divya Koura, Roni Tamari, Muhammad Umair Mushtaq, Joseph Maakaron, Joseph Rimando, Vanessa E. Kennedy, Sagar S. Patel, Chad Hudson, Michael R. Loken, Christopher A. Slapak, Deborah M. Lloyd, Darren A. Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Guy Mundelboim, Guangwu Guo, Huanying Gary Ge, Bin E. Li, Juliana Xavier-Ferrucio, Sharon L. Hyzy, Michelle I. Lin, Glen D. Raffel and Brenda W. Cooper, 12 May 2026, Nature Medicine.
DOI: 10.1038/s41591-026-04362-1
This work was supported by Vor Biopharma. Several co-authors were employees of the company when the work was conducted.
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Scientists Discover That Male and Female Hearts Age in Surprisingly Different Ways
A new study reveals surprising differences in how male and female hearts age at the cellular level. The heart may age very differently from one region to another. A detailed study of mouse hearts [...]
An Ancient Virus May Hold the Secret to What Makes the Human Brain Different
Could a virus that infected chimpanzees millions of years ago help explain how the human brain became different? Researchers at Lund University have discovered that ancient viral DNA embedded in the chimpanzee genome silences [...]
Could a Nasal Spray Stop Alzheimer’s Before Memory Loss Begins?
Protecting memory from Alzheimer’s may one day involve a nasal spray, with encouraging results in animals and evidence that its particles also protect human neurons grown in the lab. Alzheimer’s disease damages the connections [...]
A sceptical guide to AI agents in drug discovery
In conversation with Dr Eric Ma, Senior Principal Data Scientist at Moderna, Dr Raminderpal Singh examines what AI agents are actually good for, where the lock-in hides and why expertise has become more valuable [...]
Study identifies new targets for antiviral drugs against coronaviruses
A study led by researchers at the University of California San Diego School of Medicine and University of California, Riverside (UCR) School of Medicine has identified new targets for antiviral drugs against coronaviruses, including [...]
“Nearly Everybody Had Given Up” – Scientists Finally Solve a 60-Year Chemistry Mystery
After more than six decades of failed attempts, chemists have achieved a breakthrough involving a class of molecules long considered too unstable to isolate. Chemists have succeeded in isolating a group of molecules that [...]
Depression Symptoms Improved in Just 48 Hours After a Single Psychedelic Dose
A single dose of psilocybin produced rapid antidepressant effects in a small Swedish clinical trial, with improvements lasting for weeks. A single dose of psilocybin, the psychedelic compound found in magic mushrooms, produced rapid [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Human Bodies Are Producing Two Billion Tons of CO2 a Year
A new study reveals that the amount of carbon dioxide produced by human metabolism has increased dramatically over three decades. The carbon dioxide produced by human bodies as they convert food into energy increased [...]
A Hidden DNA Mechanism Could Explain How 20% of Human Cancers Develop
Researchers have identified an unexpected molecular vulnerability in cancers carrying BAF mutations. Mutations found in roughly 20% of human cancers may promote tumor growth by changing how DNA is organized inside cells. Researchers have [...]
Ebola kills over 5,300 in fastest-growing outbreak on record
Africa’s latest Ebola outbreak has killed nearly 5,400 people, the vast majority of them in the Democratic Republic of Congo (DRC), according to the continent’s top health agency. Africa Centres for Disease Control and [...]
China makes early progress in using sound waves to stimulate damaged brains
Chinese researchers are testing whether focused ultrasound can help restore consciousness in patients with severe brain injuries, adding to a growing international effort to use sound waves to stimulate deep brain structures without surgery. [...]
Micro-drones fly through the body thanks to ultrasound
At the EPFL, micro-drones have been developed that can be moved without a motor or battery.No motors, no batteries, no electronics on board, just small cavities that convert sound waves into thrust: this is [...]
A Single Enzyme Could Hold the Key to Treating a Devastating Brain Disorder
Blocking an enzyme’s production restored brain growth and healthy behaviors in mice engineered to develop Angelman syndrome, pointing to a possible treatment target. Children with Angelman syndrome begin to show difficulties with thinking and [...]
Scientists Develop a Clever New Way To Kill Cancer Cells From the Inside
Scientists have developed an experimental strategy that exploits a chemical byproduct of cancer cells to produce anticancer drugs directly inside them. Scientists in Japan have developed an experimental method that uses a chemical produced [...]
Our books are available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]















